(PharmaNewsWire.Com, November 06, 2020 ) Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans. As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables etc., is on a rise. Also, many of pharmaceutical and biotechnology firms are gearing to cater to the growing demands of medicines. This aids to the growth of market.
According MarketsandMarkets Research - The Global Viral Inactivation Market is poised to grow at a CAGR of 12.3%, to reach USD 573.0 Million.
The Key Factors Who will Drives the Market Growth?
- Rapid Growth in Pharmaceutical and Biotechnology Industries - Increasing Number of New Drug Launches - Strong R&D Investments in the Life Sciences Industry - Increasing Government Support for Pharmaceutical and Biotechnology Industries - High Incidence and Large Economic Burden of Chronic Diseases
Major Growth Opportunities:
- Increasing Pharmaceutical Outsourcing - Developing Countries Present Significant Growth Opportunities for the Market
Viral Inactivation Market Segmentation in Detailed:
Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans. As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables etc.
Based on end user, Viral Inactivation Market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.
The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Based on geography the market is segmented into North America, Europe, Asia and Rest of the World (RoW).
Major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).
Geographical Regions Mapped in Report:
The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The North America segment is further divided into Canada and the U.S. Asia segment is further divided into China, Japan, India, and Rest of Asia.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
